Recombinant humanized (from mouse) antibody expressed in CHO binding to human CD44. Bivatuzumab is a humanized monoclonal antibody against CD44 v6. It has been chemically linked to various radioisotopes for use in radiotherapy for, e.g. inoperable recurrent or metastatic head and neck cancer. It has also been linked to a cytotoxic drug mertansine to form bivatuzumab mertansine.
Figure 2 Average blood clearance curves of 186Re-BIWA 4 as assessed by ELISA.
Average blood clearance curves of 186Re-BIWA 4 as assessed by ELISA for measuring immunoreactive BIWA 4 in plasma (A) or by 186Re radioactivity measurement in serum (B). Individual data points are depicted after administration of 50 mg of BIWA 4 labeled with 31.9–108.2 mCi of 186Re to 20 HNSCC patients.
Börjesson, P. K., Postema, E. J., Roos, J. C., Colnot, D. R., Marres, H. A., Van Schie, M. H.,... & Van Dongen, G. A. (2003). Phase I therapy study with 186Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma. Clinical Cancer Research, 9(10), 3961s-3972s.
Figure 3 Blood clearance curves of 186Re-BIWA 4 for patients who received the conjugate twice.
Blood clearance was assessed by ELISA for measuring immunoreactive BIWA 4 in plasma (A–C) or by 186Re activity measurement in serum (D–F), after the first (▵) and second (○) administration of 186Re-BIWA 4 to patients 11 (A and D), 12 (B and E), and 14 (C and F).
Börjesson, P. K., Postema, E. J., Roos, J. C., Colnot, D. R., Marres, H. A., Van Schie, M. H.,... & Van Dongen, G. A. (2003). Phase I therapy study with 186Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma. Clinical Cancer Research, 9(10), 3961s-3972s.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Afuco™ Anti-CD44 ADCC Recombinant Antibody (Bivatuzumab), ADCC EnhancedThis product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant humanized (from mouse) antibody expressed in CHO binding to human CD44. Bivatuzumab is a humanized monoclonal antibody against CD44 v6.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
DrMAB-991 | Mouse Anti-CD44 Recombinant Antibody (clone BU52) | IHC, WB, IP, Inhib, Stim | Mouse IgG1 F(ab')2, κ |
HPAB-0054-YC-F(E) | Mouse Anti-CD44 Recombinant Antibody (clone mH460-16-2); Fab Fragment | ELISA, FC, IHC | Mouse Fab |
HPAB-0154-FY-F(E) | Human Anti-CD44 Recombinant Antibody (clone (hu)ARH460-16-2 variant HV2/KV1); Fab Fragment | Inhib | Humanized Fab |
HPAB-0047-YJ-F(E) | Mouse Anti-CD44 Recombinant Antibody (clone HI44a); Fab Fragment | WB, IF, FC | Mouse Fab |
HPAB-1173WJ-F(E) | Human Anti-CD44 Recombinant Antibody; Fab Fragment (HPAB-1173WJ-F(E)) | ELISA | Human Fab |
There are currently no Customer reviews or questions for TAB-727. Click the button above to contact us or submit your feedback about this product.
To accurately reference this product in your publication, please use the following citation information:
(Creative Biolabs Cat# TAB-727, RRID: AB_3111994)
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.